Fmr LLC Kronos Bio, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Fmr LLC holds 3,200 shares of KRON stock, worth $3,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,200

Previous 3,200 -0.0%

Holding current value

$3,040

Previous $4,000 25.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.02 - $1.3 $369,240 - $470,600	-362,000 Reduced 99.12%	3,200 $4,000
Q4 2023 Feb 13, 2024	BUY	$0.75 - $1.49 $270,381 - $537,156	360,508 Added 7683.46%	365,200 $456,000
Q3 2023 Nov 13, 2023	SELL	$1.23 - $2.25 $1,565 - $2,864	-1,273 Reduced 21.34%	4,692 $6,000
Q2 2023 Aug 11, 2023	BUY	$1.24 - $1.92 $2,217 - $3,432	1,788 Added 42.81%	5,965 $10,000
Q1 2023 May 11, 2023	SELL	$1.34 - $2.62 $827,537 - $1.62 Million	-617,565 Reduced 99.33%	4,177 $6,000
Q4 2022 Feb 13, 2023	SELL	$1.44 - $3.44 $1.27 Million - $3.04 Million	-882,492 Reduced 58.67%	621,742 $1.01 Million
Q3 2022 Nov 10, 2022	BUY	$3.35 - $5.55 $17,842 - $29,559	5,326 Added 0.36%	1,504,234 $5.04 Million
Q2 2022 Aug 12, 2022	SELL	$3.12 - $7.52 $1.52 Million - $3.67 Million	-487,619 Reduced 24.55%	1,498,908 $5.46 Million
Q1 2022 May 13, 2022	BUY	$6.26 - $14.42 $1.41 Million - $3.24 Million	224,733 Added 12.76%	1,986,527 $14.4 Million
Q4 2021 Feb 14, 2022	BUY	$11.35 - $21.18 $1.53 Million - $2.85 Million	134,506 Added 8.27%	1,761,794 $23.9 Million
Q3 2021 Nov 15, 2021	SELL	$18.17 - $24.7 $2.97 Million - $4.04 Million	-163,707 Reduced 9.14%	1,627,288 $34.1 Million
Q2 2021 Aug 13, 2021	BUY	$20.08 - $29.02 $36 Million - $52 Million	1,790,995 New	1,790,995 $42.9 Million

Others Institutions Holding KRON

# of Institutions

Shares Held

20.7M

Call Options Held

31.4K

Put Options Held

View Full List

About Kronos Bio, Inc.

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

More about KRON

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account